A new study found that the drug Alunbrig was superior to Xalkori in preventing disease progression in ALK inhibitor-naïve non-small cell lung cancer (NSCLC). After 25 months of treatment, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC, as assessed by an independent review committee, Takeda said at the European Society for Medical Oncology Asia meeting. The data is consistent with what Takeda showed last year after a first interim analysis. Now, the company is looking to submit the data for approvals in previously untreated patients, after fellow second-generation ALK inhibitors—Novartis’ Zykadia and Roche’s Alecensa—won their own green lights in 2017. Get the full story at fiercepharma.com.